Share on StockTwits

Amphastar Pharmaceuticals (NASDAQ:AMPH) issued its quarterly earnings data on Wednesday. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.13, StockRatingsNetwork.com reports.

A number of research firms have recently commented on AMPH. Analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. On a related note, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock. Finally, analysts at Piper Jaffray initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set an “overweight” rating and a $16.00 price target on the stock.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 10.20 on Wednesday. Amphastar Pharmaceuticals has a 52 week low of $6.67 and a 52 week high of $11.07. The stock has a 50-day moving average of $9.34 and a 200-day moving average of $9.34. The company has a market cap of $442.7 million and a price-to-earnings ratio of 49.26.

Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.